-
ENHERTU® Plus Pertuzumab Type II Variation Application Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast CancerDaiichi Sankyo2026-01-19 10:21:05ENHERTU® Plus Pertuzumab Type II Variation Application Validated in the EU as First-Line Treatment of Patients
-
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern EuropeDaiichi Sankyo2026-01-08 18:23:36Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and
-
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for ImmunotherapyDaiichi Sankyo2026-01-08 18:09:17DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with
-
ENHERTU® Type II Variation Application Validated in the EU for Previously Treated Patients with HER2 Positive Metastatic Solid TumorsDaiichi Sankyo2025-09-11 14:39:48ENHERTU® Type II Variation Application Validated in the EU for Previously Treated Patients with HER2 Positive
-
DATROWAY® Approved in the EU for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast CancerDaiichi Sankyo2025-04-08 08:00:44DATROWAY® Approved in the EU for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast
-
ENHERTU® Approved in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine TherapyDaiichi Sankyo2025-04-04 08:38:33ENHERTU® Approved in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2
-
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with HER2 Positive Metastatic Gastric Cancer at Interim Analysis of DESTINY-Gastric04 Phase 3 TrialDaiichi Sankyo2025-04-04 08:37:19ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in
-
ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine TherapyDaiichi Sankyo2025-03-06 15:57:51ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic
-
Datopotamab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast CancerDaiichi Sankyo2025-01-31 15:16:20Datopotamab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with Previously Treated
-
Survey reveals: 88% of Western Europeans would like better information on breast cancer, misconceptions and lack of awareness of the disease still prevailDaiichi Sankyo2025-01-22 06:59:30Survey reveals: 88% of Western Europeans would like better information on breast cancer, misconceptions and
